Structuring Milestone Payouts in Phase 3 Oncology Drug Licensing Deals
Biotech founders often agree to back-weighted milestone schedules that leave them cash-starved during costly Phase 3 clinical trials. Here is how to negotiate upfront developmental tranches.
Amit KasliwalCEO & Founder, Dehurdle
March 26, 20234 min read
The Developmental Milestone Tranche Script
Recommended Spoken Script
"To ensure our Phase 3 trial enrollment meets the 18-month FDA timeline, we require a $45M upfront licensing payment and $30M upon First Patient Dosed. Back-weighting milestones solely to NDA approval forces unnecessary dilution and risks study pacing."
The 2-Minute Practice Drill
2-Minute Spoken Drill
The 2-Minute Practice Drill
Practice biopharma licensing negotiations in Dehurdle.